NRx Q2 2026: net loss $18M, cash $26.7M; FDA ketamine ANDA only needs attestation

NRX Pharmaceuticals, Inc.

FDA review of ANDA for preservative-free ketamine found no drug-related major deficiencies; only manufacturer's attestation submitted, aiming for 2026 approval.
Closed underwritten public offering for gross proceeds of $22.3M; cash at June 30, 2026 was $26.7M vs $7.8M at Dec 31, 2025.
Selected by DARPA as prime contractor for SPARC-TMS trial of NRX-101 with robotic TMS; non-dilutive funding >$11.5M.
Appointed Glenn Tyson as first Chief Commercial Officer; initiated commercial scale manufacturing of 5M ketamine doses.
Net loss for six months ended June 30, 2026 was $18.0M vs $23.1M in 2025; net operating loss $11.3M vs $7.6M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.